Strategies to Ensure Endpoint Reliability in Rare & Orphan Disease Research
Signant Health
Jun 30, 2022
Orphan/rare disease trials present unique challenges—small patient populations, geographically dispersed investigators, and the need for specialized outcome measures are just a few.
At Signant, we leverage more than 25 years of expertise to help you navigate these complexities and ensure reliable, high-quality data. From neurodevelopmental assessments to quality-of-life measures, we provide tailored solutions for orphan disease research including:
- Electronic Clinician Ratings
- Rater Training & Qualification
- COA data analytics
- Central ratings and reviews
- Scientific oversight
Click to read our brochure and learn how Signant is driving success in orphan disease research.
